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ABSTRACT
Objective: To assess whether hereditary myopathy with early respiratory failure (HMERF) due to
the c.951434T.C; (p.Cys31712Arg) TTNmissense mutation also includes a cardiac phenotype.
Method: Clinical cohort study of our HMERF cohort using ECG, 2D echocardiogram, and cross-
sectional cardiac imaging with MRI or CT.
Results: We studied 22 participants with the c.951434T.C; (p.Cys31712Arg) TTN missense
mutation. Three were deceased. Cardiac conduction abnormalities were identified in 7/22 (32%):
sustained atrioventricular tachycardia (n 5 2), atrial fibrillation (n 5 2), nonsustained atrial tachy-
cardia (n 5 1), premature supraventricular complexes (n 5 1), and unexplained sinus bradycardia
(n 5 1). In addition, 4/22 (18%) had imaging evidence of otherwise unexplained cardiomyopathy.
These findings are supported by histopathologic correlation suggestive of myocardial cytoskele-
tal remodeling.
Conclusions: Coexisting cardiac and skeletal muscle involvement is not uncommon in patients
with HMERF arising due to the c.951434T.C; (p.Cys31712Arg) TTNmutation. All patients with
pathogenic or putative pathogenic TTNmutations should be offered periodic cardiac surveillance.
Neurology® 2016;87:1031–1035
GLOSSARY
HMERF 5 hereditary myopathy with early respiratory failure; LV 5 left ventricular; MFM 5 myofibrillar myopathy; NIV 5
noninvasive ventilation; RV 5 right ventricular.
Hereditary myopathy with early respiratory failure (HMERF) is an autosomal dominant disor-
der arising due to missense mutations in the fibronectin III domain of the TTN gene, most
commonly c.951434T.C; (p.Cys31712Arg).1 HMERF is characterized by adult onset of distal
or proximal muscle weakness in association with early respiratory muscle weakness, which may
be the presenting feature and require noninvasive ventilation. Muscle biopsy findings are largely
nonspecific, although myofibrillar myopathy and cytoplasmic bodies are described.2
Other skeletal myopathies caused by missense mutations in titin include tibial muscular dys-
trophy due to heterozygous mutations in the C-terminus3 and limb-girdle muscular dystrophy
type 2J arising from recessive mutations at the same locus.4 Cardiac complications in these
phenotypes have not been reported previously.1,3–5 Conversely, heterozygous truncating TTN
mutations are a recognized cause of dilated6 and restrictive7 cardiomyopathies without apparent
skeletal muscle involvement. However, the rare coexistence of skeletal and cardiac muscle disease
in recessive truncating titin mutations6 raises the possibility that cardiac involvement may occur
in other titinopathies. This has implications for the surveillance of those at risk. To address this,
we carried out the first systematic cardiac study in HMERF using multimodal structural and
functional cardiac imaging.
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Table 1 Clinical features of the UK hereditary myopathy with early respiratory failure cohort
Patient
and
family ID Sex
Age at
onset, y DisD, y Skeletal muscle pattern Function
PFTs (%
predicted)
NIV Cardiac Hx, Ix, and Mx 12-Lead ECG Echo summaryFEV1 FVC
1 A F 30 14 Distal LL Unaided 72 71 N No medication Low-amplitude p waves Segmental LV hypokinesis
and YLV EF 50%–55%
2 B M 37 6 Distal . proximal LL . UL AFO 52 68 N Ramipril for high BP Normal Normal
3 B M 33 13 Distal and proximal LL and distal UL Unaided 83 85 Y No medication Normal Grade 1 DD–NFA
4 B F 40 10 Distal and proximal UL and LL and axial Unaided uk 53 N Propranolol intermittently;
24-hour ECG 5 11 beats AT
Tachycardic with premature
atrial ectopics
E-E9 8–15, possible diastolic
LV dysfunction
5 B M 45 2 Mild distal UL and LL Unaided 67 70 N Palpitations; no meds; 24-hour
ECG 5 normal
Normal Normal
6 B F 60 14 Mild distal LL weakness Unaided 67 62 N No medication Bradycardic: 55 bpm E-E9 8–15, possible diastolic
LV dysfunction
7 B M 16 32 Distal and proximal LL; distal UL Stick uk 73 N No medication Notched p waves Poor view
8 B F 29 14 Distal and proximal LL Unaided 70 64 Y AVNRT: ablation; no meds Normal Normal (LV EF low normal 55%)
9 B M 35 30 Distal and proximal UL and LL WC 33 32 Y Lisinopril for high BP Premature SV complexes Grade 1 DD–NFA
10 B M 44 15 Distal and proximal UL and LL WC 67 63 Y Palpitations; atorvastatin Normal Small LV cavity
11 B M 20 34 Distal and proximal UL and LL Crutch and AFO 57 55 N 2012: Perindopril 4 mg,
bisoprolol 2.5 mg; 2014:
perindopril 4 mg, bisoprolol
5 mg
Low-amplitude p waves,
normal PR, flattened T
waves (evolving over
2 years)
2012: LV EF 40%–45%; mild-
moderate imp RV; 2013: LV EF
50%; 2014: LV EF .55%, low
normal RV function, segmental
CM; 2015: LV EF 50%
12 B F 46 10 Distal and proximal LL; distal UL WC 73 71 N No medication Premature atrial complexes Normal
13 C M 35 6 Distal and proximal LL; proximal UL WC uk 77 N No medication Low-amplitude notched p
waves, nonspecific flattened
T waves (evolving over 3 years)
2014: LV EF 50%; 2015: LV
EF 55%
14 C F NA NA Nil Unaided uk 77 N No medication Normal Normal
15 D M 28 5 Distal and proximal UL and LL AFO uk 70 N No medication Normal Normal
16 E M 30 27 Distal LL and UL uk uk 68 N No medication uk Normal
17 F M 39 8 Distal LL and UL uk uk uk uk No medication Normal Normal
18 G M 27 15 Distal and proximal LL . distal UL AFO 55 56 N No medication uk Normal
19 H M 30 33 Distal LL and UL uk uk 56 Y SVT; bisoprolol uk uk
20* I M 45 4 Proximal and distal LL; proximal UL Stick 67 71 N No cardiac hx or medication uk uk
21* J M uk uk Proximal and distal LL; mild proximal UL uk uk uk Y PPM, AVR; uk medication Atrial fibrillation uk
22* C M 44 30 Distal . proximal LL . UL WC 33 27 Y 2010: Bisoprolol 2.5 mg;
furosemide 20–40 mg; 24-hour
ECG: AF with variable rate
Atrial fibrillation 2007: LV EF 45%–50%; 2013:
LV EF 50%
Abbreviations: AF5 atrial fibrillation; AFO5 ankle foot orthosis; AT5 atrial tachycardia; AVNRT5 atrioventricular nodal reentrant tachycardia; AVR5 aortic valve replacement; BP5 blood pressure; bpm5 beats per minute;
CM5 cardiomyopathy; DD5 diastolic dysfunction; DisD5 disease duration; EF5 ejection fraction; FEV15 forced expiratory volume in 1 second; FVC5 forced vital capacity; Hx5 history; imp5 impaired; Ix5 investigations;
LL 5 lower limb; LV5 left ventricular; Mx 5 management; NA5 not applicable; NFA 5 normal for age; NIV 5 noninvasive ventilation; PFTs 5 pulmonary function tests; PPM5 permanent pacemaker; PR5 PR interval; RV5
right ventricular; SVT 5 supraventricular tachycardia; UL 5 upper limb; uk 5 unknown; WC 5 wheelchair; * 5 deceased patients.
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METHODS All participants known to the John Walton Mus-
cular Dystrophy Research Centre, Newcastle upon Tyne, United
Kingdom, with the c.951434T.C; (p.Cys31712Arg) TTN mis-
sense mutation had a 12-lead ECG and echocardiogram
requested as part of routine clinical care. All available cardiac
test results were reviewed. Thereafter, all participants residing
within the North East of England were invited to attend for
a cardiac MRI, irrespective of cardiac symptomatology or initial
findings. Where participants were unable to tolerate MRI, cardiac
CT scan was offered.
All cardiac MRIs were performed on a 1.5T Siemens MRI
scanner using a standardized cardiomyopathy protocol, with black
blood anatomical, multiplanar short tau inversion recovery, multi-
planar cines—including short axis stack for ventricular function,
multiplanar cines, and delayed enhancement sequences obtained
with gadoterate meglumine (Dotarem; Guerbet, Villepinte,
France). All cardiac CT imaging was performed on a Siemens dual
source CT scanner retrospectively gated at low dose for functional
information only with a Flash mode delayed enhancement series
7 minutes following iohexol (Omnipaque; GE Healthcare, Cleve-
land, OH) administration.
Histopathologic correlation. Based on previous reports of
desmin as a marker of cardiac dysfunction,8 we undertook anal-
ysis of frozen myocardial samples collected postmortem from 3
patients with HMERF.
Immunohistochemistry. Immunolabeling for b-spectrin
(clone RBC2/3D5), desmin (DAKOM0760; Glostrup, Denmark),
myotilin (NCL-Myotilin; Leica Biosystems, Newcastle, UK), VCP
(BD Biosciences, East Rutherford, NJ), ubiquitin (NCL-UBIQm;
Leica Biosystems), and p62 (Abcam ab56416; Cambridge, UK) was
undertaken.
Western blot. Myocardial samples from patients and age-
matched controls with no reported cardiac pathology were
homogenized and run on sodium dodecyl sulfate polyacrylamide
gel electrophoresis (4%–12% gradient). Immunoanalysis was per-
formed using the antibody against desmin. Immunoblots were
visualized with SuperSignal West Pico Chemiluminescent Sub-
strate detection using AlphaInnotech FluorChem Q platform and
AlphaView software v3.0. All tests were performed in duplicate.
Standard protocol approvals, registrations, and patient
consents. Clinical assessments were undertaken as routine clin-
ical care. Consent and ethical approval was in place for the histo-
pathologic studies.
RESULTS We identified 22 participants with the
c.951434T.C; (p.Cys31712Arg) TTN mutation.
Three were deceased. Eighteen attended for echocar-
diogram, of whom 6 subsequently had cardiac MRI
and 4 cardiac CT imaging. Two individuals failed to
attend planned MRI scans. Cross-sectional imaging
was not requested in 7 patients due to geographic
dispersion. Clinical features are outlined in table 1.
We identified conduction abnormalities in 32%
(7/22) of patients. These included sustained atrioven-
tricular tachycardia (8B and 19H), nonsustained atrial
tachycardia (4B; figure, A), premature supraventricular
complexes (9B), unexplained sinus bradycardia (6B),
and atrial fibrillation (21J and 22C). Patients 8B and
19H were treated with bisoprolol and 8B underwent
catheter ablation. Patients 5B and 10B had a history of
Figure Clinical and pathologic features of cardiac involvement in hereditary myopathy with early respiratory
failure (HMERF)
(A) Twenty-four-hour ECG demonstrates nonsustained atrial tachycardia (patient 4B). (B) Cardiac MRI of 11B demonstrates
subepicardial fibrosis (arrow). (C) Hematoxylin & eosin staining of myocardium in controls (C1 and C2) and patients with
HMERF (20* and 21*). (D) Western blot staining for desmin (DES) and myosin heavy chain (MHC).
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palpitations without specific diagnosis being reached
despite investigation.
Asymptomatic global left ventricular systolic dys-
function was evident in 4/22 (18%) patients (1A,
11B, 13C, and 22*) on echocardiogram (tables 1
and 2). Although none had chamber dilation, the
findings were compatible with nonischemic cardio-
myopathy. Two were known to have reduced left
ventricular (LV) ejection fraction at study onset
(11B and 13C), and one was identified with mild
right ventricular (RV) systolic dysfunction in the
course of the study (1A). We identified subepicardial
fibrosis in 11B on late gadolinium-enhanced MRI
(figure, B). None had other lifestyle, history, or med-
ical risk factors to explain their cardiac features.
Four individuals had evidence of possible or defi-
nite LV diastolic dysfunction by E-E9 measures on
echocardiography. Patient 9B was on maintenance
lisinopril for hypertension, but none of the others
(3B, 4B, 6B) had any history of cardiac disease, car-
dioactive medication use, or prior cardiology assess-
ment. Patients 6B and 9B underwent cross-sectional
cardiac imaging with CT and mild diastolic impair-
ment was confirmed in 6B (tables 1 and 2).
Response to treatment. Participant 11B demonstrated
sustained improvement in cardiac function in the
2012–2015 period following initiation of perindopril
and bisoprolol therapy. Left ventricular function
improved in patient 22* after commencing b-blocker
therapy (table 1).
Relationship to disease onset. The age range of individ-
uals developing cardiomyopathy overlapped with
those without (40–65 and 33–65 years, respectively)
and with disease duration (6–34 and 2–33 years,
respectively). Cardiomyopathy emerged 4–30 years
after first skeletal muscle symptoms (table 1).
Relationship to respiratory disease.We assessed the rela-
tionship of confirmed ventricular systolic dysfunction
at any time with respiratory disease and noninvasive
ventilation (NIV) use. No relationship was identified
between ventricular systolic impairment and respiratory
disease (reduction in pulmonary function tests of 25%
or more from predicted) or use of NIV (p 5 0.2722
and p 5 0.2778, respectively; Fisher exact test).
Histopathologic correlation. Immunohistochemistry.Myo-
cardial tissue preservation was satisfactory in patient
20*, degraded in patient 21* (figure, C), and unsuit-
able for further analysis in patient 22*. Immunolab-
eling for myofibrillar proteins was unremarkable and
did not demonstrate abnormal protein accumulation
(not shown).
Immunoblot. Desmin expression was upregulated
(approximately 2.5-fold) in patient 20* compared to
controls, suggesting myocardial cytoskeletal remodel-
ing.8 Patient 21* showed reduced desmin expression
consistent with extensive postmortem delay (figure, D).
DISCUSSION Our findings show that cardiac
involvement is not uncommon in patients with the
c.951434T.C (p.Cys31712Arg) TTNmissense muta-
tion. Conduction abnormalities occurred in a third of
patients, with atrial fibrillation and sustained paroxysmal
atrioventricular tachycardia most frequently identified
(2/22; 9% each). The prevalence of the latter arrhythmia
Table 2 Cardiac MRI and CT features
Patient
and
family ID Ix
RV: Ejection
fraction, %
LV: Ejection
fraction, % Fibrosis?
Corrected end
LV diastolic
volume, mL/m2
Corrected end
RV diastolic
volume, mL/m2 Overall impression
1 A MRI 44 60 N 51 (56–96) 63 (48–112) (1) Subtle dyssynchronous ventricular
contractions; (2) mild RV impairment
2 B MRI 64 70 N 56 (57–105) 59 (61–121) Normal
5 B CT 57 60 N Normal
6 B CT 50 74 N Subtly abnormal: mildly enlarged atria
7 B MRI 2015 45 53 N 65 (57–105) 77 (61–121) Normal (no cardiac medication)
MRI 2012 38 45 N 90 (57–105) 109 (61–121) Possible early cardiomyopathy: LVEF and
LV volume in URN; no medication
8 B MRI 56 57 N 70 (56–96) 69 (48–112) Normal
9 B CT 63 N Normal
10 B CT 72 N Normal
11 B MRI 41 60 Y 67 (57–105) 92 (55–105) (1) Subepicardial fibrosis; (2) RV
impairment without dilation of RV/PA
13 C MRI 31 38 N 49 (47–92) 64 (61–121) Mild nondilated, nonischemic
cardiomyopathy
Abbreviations: Ix 5 investigations; LV 5 left ventricle; LVEF 5 left ventricular ejection fraction; PA 5 pulmonary artery; RV 5 right ventricle; URN 5 upper
range of normal.
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is significantly higher than seen in the general popula-
tion (9% vs 0.2%; p 5 0.0026; Fisher exact test).9
Additionally, cardiomyopathy was identified in
18% (4/22). Importantly, this was responsive to stan-
dard cardioactive therapies. Interestingly, the presence
of either LV or RV dysfunction was independent of
respiratory failure, suggesting the mechanism is not
secondary to nocturnal hypoventilation, restrictive pul-
monary physiology, or cor pulmonale. The etiology of
the diastolic dysfunction observed is uncertain given
the absence of LV hypertrophy or significant fibrosis.
Diastolic dysfunction is a recognized feature of cardio-
vascular aging and consequently, is the most likely
explanation for our findings. However, a disease-
specific association cannot be excluded.
As a recently recognized cause of myofibrillar
myopathy (MFM), the TTN mutation causing
HMERF is now included in genetic testing panels
for MFM.2 Cardiac involvement in other myofibrillar
myopathies, also encompassing arrhythmia and cardio-
myopathy, is well-recognized, with an estimated prev-
alence of 30%.10 Our findings are in keeping with this.
The main limitation of our study is its pragmatic
nature as it was conducted in the context of routine
clinical health care. Consequently, the echocardio-
grams were performed and reported by several—albeit
experienced—echo-technicians and the CT scans were
reported retrospectively. While MRI remains the gold
standard investigation for assessment of ventricular
function, use of CT in this population, with neuro-
muscular respiratory failure and NIV, enabled more
patients to undergo cross-sectional cardiac imaging.
Although the 2 modalities are not directly comparable,
where imaging is undertaken longitudinally using the
same method, an assessment of change can be made.
As the full spectrum of cardiac and skeletal muscle
phenotypes associated with TTN mutations remains
unknown, patients with pathogenic or putative patho-
genicTTNmutations should be offered periodic cardiac
surveillance. However, based on the findings we present
here, some of the observed abnormalities may be due to
normal aging, and not TTN cardiomyopathy per se.
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